Jaguar health regains compliance with nasdaq's bid price requirement

Jagx's securities continue to be listed and traded on nasdaq jaguar to report pivotal phase 3 ontarget trial results for its cancer supportive care drug crofelemer on or before july 23, 2024 san francisco, ca / accesswire / june 26, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that on june 25, 2024 the company received formal notice from the nasdaq stock market llc ("nasdaq") that jaguar has regained compliance with nasdaq's minimum bid price requirement. "we are very happy that jaguar has regained compliance with nasdaq.
JAGX Ratings Summary
JAGX Quant Ranking